REFERENCES:

Cheung KL et al. Preoperative endocrine therapy for breast cancer. Endocrine-Related Cancer 1999;7(3):131-141. Full Text

Dixon JM et al. The effects of neoadjuvant anastrozole (Arimidex)on tumor volume in postmenopausal women with breast cancer: A randomized, double-blind, single-center study. Clin Cancer Res 2000;6(6):2229-35. Abstract

Dixon JM et al. Lessons from the use of aromatase inhibitors in the neoadjuvant setting. Endocrine-Related Cancer 1999;6(2):227-230. Full Text

Dixon JM et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 2001;66:191-9. Abstract

Dixon JM et al. Phase IIb study of neoadjuvant exemestane (EXE) in locally advanced breast cancer. Proc ASCO 2001; Abstract 1908.

Ellis MJ et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-16. Abstract

Ellis MJ. Preoperative endocrine therapy for older women with breast cancer: Renewed interest in an old idea. Cancer Control 2000;7(6):557. Full Text

Gazet JC et al. Estrogen-receptor-directed neoadjuvant therapy for breast cancer: Results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. Ann Oncol 2001;12:685-91. Abstract

Geisler J et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 2001;7:1230-6. Abstract

Gregory RK et al. Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy. Breast Cancer Res Treat 2000;59(2):171-5. Abstract

Hoff PM et al. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer 2000;88(9):2054-60. Abstract

Makris A et al. Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer 1999;85(9):1996- 2000. Abstract

Milla-Santos A et al. Anastrozole (A) as neoadjuvant (NEO) therapy for hormone-dependent locally advanced breast cancer (LABC) in post-menopausal (PM) patients (pts). Breast Cancer Res Treat 2001; Abstract 302.

Pujol P et al. Neoadjuvant tamoxifen for operable breast cancer: A need for phase III studies? Cancer Detect Prev 2000;24(5):445-51. Abstract

Back | Top of Page